Tilsuprost is an iminoprostacyclin derivative patented by Hoechst A.-G. as stable prostacyclin analog useful cytoprotective agent. In preclinical models, Tilsuprost given just before induction of pancreatitis partly prevented the impairment of mitochondrial oxidative and phosphorylative functions, however, these positive effects were limited in acute pancreatitis preceded by acute ethanol intake.